Conclusions: Future real-world case series involving patients with multiple sclerosis
(MS) or neuromyelitis optica spectrum disorder (NMOSD) who are infected
with COVID-19 will be essential for determining optimal management strategies.
Currently, clinical decision-making is primarily guided by expert opinion and
existing recommendations.